Close Menu

NEW YORK – A new study published this week in Clinical Cancer Research found that NOTCH mutations downregulate NOTCH signaling and correlate with better responses to immune checkpoint inhibitor therapy in non-small cell lung cancer patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.